These results suggest that combined treatment with RIPK2/NF-κB/MGMT signaling pathway inhibitors and TMZ enhances the therapeutic efficacy in RIPK2-positive TMZ-resistant glioma. The gene discussed is NFKB1; the disease is central nervous system cancer.